SCHEMBL2221695

SCHEMBL2221695

O=C(Nc1cc(Cl)ccc1N1CCC(CCN2CCC(O)CC2)CC1)c1cccc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
CXCR3 P49682 4/20 0.50
CACNA1I Q9P0X4 2/20 0.50
KCNH2 Q12809 1/20 0.50
WDR5 P61964 1/20 0.50
IRAK4 Q9NWZ3 4/20 0.49
GAA P10253 2/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HTT P42858 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 1/20 0.48
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KCNMA1 Q12791 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2221639 0.91 KMT2A (0.60) KMT2AMEN1CXCR3CACNA1IKCNH2
SCHEMBL2267054 0.87 WDR5 (0.56) KMT2AMEN1CXCR3CACNA1IKCNH2
SCHEMBL2224401 0.87 TDP1 (0.57) KMT2AMEN1CXCR3WDR5GAA
SCHEMBL2223692 0.86 KMT2A (0.56) KMT2AMEN1CXCR3WDR5IRAK4
SCHEMBL2271450 0.85 CXCR3 (0.69) KMT2AMEN1CXCR3CACNA1IKCNH2
SCHEMBL2221531 0.85 KMT2A (0.55) KMT2AMEN1CXCR3WDR5IRAK4
SCHEMBL2220991 0.85 LMNA (0.53) KMT2AMEN1CXCR3WDR5IRAK4
SCHEMBL2221503 0.84 MEN1 (0.56) KMT2AMEN1CXCR3CACNA1IKCNH2
SCHEMBL2222665 0.84 MEN1 (0.56) KMT2AMEN1CXCR3CACNA1IKCNH2
SCHEMBL2224692 0.84 KMT2A (0.53) KMT2AMEN1CXCR3WDR5GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US claimed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO claimed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 KMT2A 3936/4885MEN1 3640/4885CXCR3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.